Találati lista | Tudóstér

001-es BibID:	BIBFORM118901
035-os BibID:	(WoS)001152827800001 (Scopus)85187190105
Első szerző:	Csiki Emese (onkoradiológus)
Cím:	Stereotactic body radiotherapy in lung cancer : a contemporary review / Csiki Emese, Simon Mihály, Papp Judit, Barabás Márton, Mikáczó Johanna, Gál Kristóf, Sipos Dávid, Kovács Árpád
Dátum:	2024
ISSN:	1219-4956 1532-2807
Megjegyzések:	The treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine the size, localization and extent of the lung tumor. The introduction of novel and further developed planning (contouring guidelines, diagnostic image application, planning systems) and delivery techniques (motion management, image guided radiotherapy) led to lower rates of side effects and more conformal target volume coverage. The purpose of this study is to summarize the current developments, randomised studies, guidelines about lung SBRT, with emphasis on the possibility of increasing local control and overall rates in "fit," operable patients as well, so SBRT would be eligible in place of surgery.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Pathology & Oncology Research. - 161 (2024), p. 1-13. -
További szerzők:	Simon Mihály Papp Judit (1971-) (onkoradiológus) Barabás Márton Mikáczó Johanna Gál Kristóf (1994-) (orvos) Sipos Dávid Kovács Árpád (1979-) (onkoradiológus, klinikai onkológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM118614
035-os BibID:	(cikkazonosító)1611589 (WoS)001152827800001 (Scopus)85186741412
Első szerző:	Kovács Árpád (onkoradiológus, klinikai onkológus)
Cím:	LINAC-based SBRT in treating early-stage NSCLC patients : single institution experience and survival data analysis / Kovács Árpád, Trási Krisztina, Barabás Márton, Gál Kristóf, Csiki Emese, Sipos Dávid, Papp Judit, Simon Mihály
Dátum:	2024
ISSN:	1219-4956 1532-2807
Megjegyzések:	Aim: This single institute prospective study aimed to evaluate the feasibility of LINAC-based stereotactic body radiotherapy (SBRT) in treating patients with early-stage non-small cell lung cancer (NSLSC). We focused on the survival data with the local and distant control profiles and the cancer- and non-cancer-specific survival. Treatment-related side effects were also collected and analyzed.Methods: Patients with early-stage NSCLC between January 2018 and October 2021 were included in our prospective study; a total of 77 patients receiving LINAC-based SBRT were analyzed. All patients had pretreatment multidisciplinary tumor board decisions on SBRT. The average patient age was 68.8 years (median: 70 years, range: 52-82); 70 patients were in ECOG 0 status (91%), while seven patients were in ECOG 1-2 status (9%). 52% of the patients (40) had histologically verified NSCLC, and the other 48% were verified based on PETCT results. We applied the SBRT scheme 8 x 7.5 Gy for central tumors (74%) or 4 x 12 Gy for peripheral tumors (26%).Results: The mean follow-up time was 25.4 months (median 23, range 18-50). The Kaplan-Meier estimation for overall survival in patients receiving LINAC-based SBRT was 41.67 months. Of the 77 patients treated by SBRT, death was reported for 17 patients (9 cases cancer-specific, 8 cases non-cancer specific reason). The mean local tumor control was 34.25 months (range 8.4-41), and the mean systemic control was 24.24 months (range 7-25). During the treatments, no Grade I-II were reported; in 30 cases, Grade I non-symptomatic treatment-related lung fibrosis and two asymptomatic rib fractures were reported.Conclusion: In the treatment of early-stage NSCLC, LINAC-based SBRT can be a feasible alternative to surgery. Although we reported worse OS data in our patient cohort compared to the literature, the higher older average age and the initial worse general condition (ECOG1-2) in our patient cohort appear to be the reason for this difference. With the comparable local control and survival data and the favorable side effect profile, SBRT might be preferable over surgery in selected cases.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk VATS NSCLC SBRT LINAC-based SBRT early stage
Megjelenés:	Pathology & Oncology Research. - 30 (2024), p. 1-6. -
További szerzők:	Trási Krisztina Barabás Márton Gál Kristóf (1994-) (orvos) Csiki Emese (1986-) (onkoradiológus) Sipos Dávid Papp Judit (1971-) (onkoradiológus) Simon Mihály (1981-) (Fizikus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: